Protein kinase C theta (PKC-θ) is a serine/threonine specific protein kinase. It is largely expressed in the T-cells and CD28 signaling. PKC-θ phosphorylates diverse proteins that are involved in the various cellular signaling pathways. Activated PKC-θ in turn activates other transcription factors that control the proliferation and differentiation of T-cells. PKC-θ is considered to be an interesting therapeutic target due to its crucial role in the proliferation, differentiation and survival of T-cells. In the present study, we have performed ligand-based CoMFA study on a series of pyridylpyrazolopyridine derivatives as PKC-θ inhibitors. An acceptable CoMFA model (q 2 =0.544; ONC=4; r 2 =0.876) was developed and validated by Bootsrapping and progressive sampling. The CoMFA contour map suggested the regions to increase the activity. Bulky substitutions in R 2 position of the piperizine ring could increase the activity. Similarly positive, small substitution in the R 1 position of the Pyridine ring could considerably increase the activity. Our work could assist in designing more potent PKC-θ inhibitors of pyridylpyrazolopyridine derivatives.
Introduction
Protein kinase C (PKC) belongs to the family of serine/threonine kinases. PKCs play an important role in the signal transduction pathway in various cells [1] . Based on the sequence and domain similarities, they are divided into three subfamilies [2] , a conventional, novel and atypical PKCs. The conventional PKCs include PKC α, β, γ whereas the novel and atypical PKCs are PKC δ, θ, η, ε and PKC ζ, λ respectively [3] . Each isoforms has unique roles in the regulation of cellular functions [2] . PKC-θ is a member of novel PKCs which are Ca2 + -independent PKC subfamily. PKC-θ is primarily expressed in T lymphocytes and muscle cells [4] [5] [6] . Many studies have indicated that PKC plays a critical role in mature T cell activation [7] . Activation of PKC-θ in turn activate a range of transcription factors in the nuclei of T-cells such as NF-κB, NFAT, c-Jun, c-Fos and AP-1 [8] .
Due to the role it plays in proliferation, differentiation and survival of the T-cells [9] , PKC θ is considered to be an attractive target for a diverse immunological and T-cell mediated diseases. New PKC-θ inhibitors are being developed and tested for their potency against various T-cells mediated diseases such as rheumatoid arthritis, transplantation and multiple sclerosis. Among the many designed inhibitors, staurosporines and related bisindolylmaleimides show good inhibitory activity against the PKC isoforms [10] . But, meticulous study on these compounds revealed that, these inhibitors can inhibit other kinase families more potently than the targeted PKC isotypes. Hence, the need to design a potent and selective inhibitor for PKC-θ becomes highly essential. Our group has reported several research and review articles on various insilico techniques such as application of partial charges, molecular docking, and 3D-QSAR studies [11] [12] [13] [14] [15] . In this study, we have performed a ligand-based CoMFA study on series of pyridylpyrazolopyridine derivatives have carried out.
Methodology

Data Set
A series of 24 pyridylpyrazolopyridine derivatives were reported by Jimenez et al., was taken for this study [16] . All the reported IC 50 values were converted into pIC 50 values ((-logIC 50 ). All the structures of the dataset were drawn using sketch program of SybylX2.1 [17] . The structure of the most active compound 24 was drawn and geometry of the molecule was optimized using sybyl Tripos force field after which Gasteiger charges were applied as partial charge. The energy optimized conformation of compound 24, was taken as the active conformation to draw the rest of the molecules in the dataset. The molecules taken for the study are shown in Table 1 . 2.2. CoMFA 3D-QSAR technique helps in understanding of the biological properties based on the steric (van der Waals interactions) and electrostatic (Coulombic interactions) fields surrounding the compounds of the dataset. CoMFA was developed by Cramer et al [18] . Aligned molecules were placed in the 3D cubic lattice with the grid spacing of 2.0 Å. Electrostatic and steric fields in CoMFA were calculated from Coulomb and LennardJones potentials, respectively. The fields were generated using sp 3 carbon probe atom carrying +1 charge and van der Waals radius of 1.50 Å. The energy cut off of 30.0 kcal/mol was set to 30.0 kcal/mol to reduce the distortion due to extreme energy in the model. A leave-one-out (LOO) PLS was performed to determine the cross-validated r2 (q2) and the optimum number of components and minimum standard error of prediction (SEP) in the model. CoMFA descriptors were used as independent variables and pIC 50 values were used as dependent variables in the PLS analysis. The cross-validated correlation coefficient (q 2 ) that was obtained was considered for further analysis. The noncross-validated analysis was performed to determine conventional Pearson correlation coefficient (r 2 ), standard error of estimate (SEE) and Fischer's ratio (F) using the ONC previously obtained from the cross-validation method. The developed model was validated to check its predictability using Bootstrapping and Progressive sampling. Bootstrapping of 100 runs and progressive sampling of 100 samplings with 2 to 100 bins was performed to validate the models.
Results and Discussion
CoMFA Model
Ligand-based CoMFA model was developed for a series of pyridylpyrazolopyridine derivatives possessing inhibitory activity against PKC-θ kinase. Lowest energy conformer of the most active compound 24 was considered as template. All the molecules were then aligned over the template using alignment method based on the common substructure. The common substructure of the compounds from template molecule 24 is shown in Fig.  1 and the alignments of the compounds are displayed in Fig. 2 Table 2 . The experimental and predicted activity values of the molecules obtained for the ligandbased CoMFA model is tabulated in Table 3 . The scatter plot and contour map for the same are shown in Fig. 3 and Fig. 4 respectively. 
CoMFA Contour Maps
The contour maps were developed by using the STDEV*COEFF field type with the default 80% and 20% level contributions for favorable and unfavorable regions, respectively. The most active compound 24 was shown superimposed inside the contour map. The steric contour map of the ligand-based CoMFA is shown in Fig. 4a . The green color signifies regions that favor sterically bulky groups and yellow color signifies the regions that are not favored for bulky substitution. 
Conclusion
The critical role of PKC-θ in proliferation, differentiation and survival of T-cells makes it an interesting therapeutic target for autoimmune diseases. In this study, we have taken a series of pyridylpyrazolopyridine as potent antagonist for PKC-θ kinase. The ligandbased CoMFA model was developed with acceptable statistical values. The developed model was validated using bootstrapping and progressive sampling. The validation results showed that the model is predicable and robust. Futhermore, the analysis of the contour maps generated for the ligand-based CoMFA model highlighted the regions to increase the activity of the compounds. The overall contour map results suggest that bulky positive substitution in R2 position could enhance the activity. Likewise, position substitution in R3 position can help to enhance the activity of the compounds. Bulky substitution must be strongly avoided in the R1 position to increase the activity of these compounds. The useful information provided by the contour maps could be used to develop a more potent compound of pyridylpyrazolopyridine series as PKC-θ inhibitor.
